vs

Side-by-side financial comparison of HARTE HANKS INC (HHS) and NEKTAR THERAPEUTICS (NKTR). Click either name above to swap in a different company.

HARTE HANKS INC is the larger business by last-quarter revenue ($39.9M vs $21.8M, roughly 1.8× NEKTAR THERAPEUTICS). HARTE HANKS INC runs the higher net margin — 5.5% vs -165.4%, a 171.0% gap on every dollar of revenue. On growth, HARTE HANKS INC posted the faster year-over-year revenue change (-15.4% vs -25.3%). HARTE HANKS INC produced more free cash flow last quarter ($-686.0K vs $-65.0M). Over the past eight quarters, NEKTAR THERAPEUTICS's revenue compounded faster (0.4% CAGR vs -6.4%).

Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

HHS vs NKTR — Head-to-Head

Bigger by revenue
HHS
HHS
1.8× larger
HHS
$39.9M
$21.8M
NKTR
Growing faster (revenue YoY)
HHS
HHS
+9.8% gap
HHS
-15.4%
-25.3%
NKTR
Higher net margin
HHS
HHS
171.0% more per $
HHS
5.5%
-165.4%
NKTR
More free cash flow
HHS
HHS
$64.3M more FCF
HHS
$-686.0K
$-65.0M
NKTR
Faster 2-yr revenue CAGR
NKTR
NKTR
Annualised
NKTR
0.4%
-6.4%
HHS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HHS
HHS
NKTR
NKTR
Revenue
$39.9M
$21.8M
Net Profit
$2.2M
$-36.1M
Gross Margin
Operating Margin
-0.3%
-126.9%
Net Margin
5.5%
-165.4%
Revenue YoY
-15.4%
-25.3%
Net Profit YoY
-596.9%
EPS (diluted)
$0.30
$-4.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HHS
HHS
NKTR
NKTR
Q4 25
$39.9M
$21.8M
Q3 25
$39.5M
$11.8M
Q2 25
$38.6M
$11.2M
Q1 25
$41.6M
$10.5M
Q4 24
$47.1M
$29.2M
Q3 24
$47.6M
$24.1M
Q2 24
$45.0M
$23.5M
Q1 24
$45.4M
$21.6M
Net Profit
HHS
HHS
NKTR
NKTR
Q4 25
$2.2M
$-36.1M
Q3 25
$-2.3M
$-35.5M
Q2 25
$-335.0K
$-41.6M
Q1 25
$-392.0K
$-50.9M
Q4 24
$7.3M
Q3 24
$142.0K
$-37.1M
Q2 24
$-27.8M
$-52.4M
Q1 24
$-171.0K
$-36.8M
Gross Margin
HHS
HHS
NKTR
NKTR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
72.7%
Q3 24
81.6%
Q2 24
58.5%
Q1 24
60.6%
Operating Margin
HHS
HHS
NKTR
NKTR
Q4 25
-0.3%
-126.9%
Q3 25
1.3%
-268.6%
Q2 25
0.1%
-324.2%
Q1 25
-0.1%
-425.8%
Q4 24
-3.3%
49.2%
Q3 24
4.0%
-142.4%
Q2 24
3.0%
-211.9%
Q1 24
0.8%
-163.7%
Net Margin
HHS
HHS
NKTR
NKTR
Q4 25
5.5%
-165.4%
Q3 25
-5.8%
-301.3%
Q2 25
-0.9%
-372.2%
Q1 25
-0.9%
-486.4%
Q4 24
24.9%
Q3 24
0.3%
-153.6%
Q2 24
-61.8%
-222.9%
Q1 24
-0.4%
-170.1%
EPS (diluted)
HHS
HHS
NKTR
NKTR
Q4 25
$0.30
$-4.67
Q3 25
$-0.31
$-1.87
Q2 25
$-0.05
$-2.95
Q1 25
$-0.05
$-0.24
Q4 24
$-0.31
$-2.07
Q3 24
$0.02
$-2.66
Q2 24
$-3.84
$-3.76
Q1 24
$-0.02
$-0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HHS
HHS
NKTR
NKTR
Cash + ST InvestmentsLiquidity on hand
$5.6M
$15.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$20.5M
$89.8M
Total Assets
$91.8M
$280.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HHS
HHS
NKTR
NKTR
Q4 25
$5.6M
$15.1M
Q3 25
$6.5M
$41.0M
Q2 25
$4.8M
$43.0M
Q1 25
$9.0M
$38.9M
Q4 24
$9.8M
$44.3M
Q3 24
$5.9M
$30.1M
Q2 24
$11.0M
$27.9M
Q1 24
$11.5M
$48.6M
Stockholders' Equity
HHS
HHS
NKTR
NKTR
Q4 25
$20.5M
$89.8M
Q3 25
$19.9M
$85.1M
Q2 25
$22.2M
$-24.2M
Q1 25
$21.4M
$13.7M
Q4 24
$21.7M
$60.7M
Q3 24
$21.0M
$48.9M
Q2 24
$20.6M
$79.7M
Q1 24
$20.0M
$126.7M
Total Assets
HHS
HHS
NKTR
NKTR
Q4 25
$91.8M
$280.4M
Q3 25
$92.7M
$301.3M
Q2 25
$95.0M
$207.5M
Q1 25
$100.6M
$256.2M
Q4 24
$101.8M
$303.9M
Q3 24
$108.1M
$308.0M
Q2 24
$109.7M
$343.3M
Q1 24
$113.4M
$396.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HHS
HHS
NKTR
NKTR
Operating Cash FlowLast quarter
$737.0K
$-65.0M
Free Cash FlowOCF − Capex
$-686.0K
$-65.0M
FCF MarginFCF / Revenue
-1.7%
-298.0%
Capex IntensityCapex / Revenue
3.6%
0.1%
Cash ConversionOCF / Net Profit
0.33×
TTM Free Cash FlowTrailing 4 quarters
$-4.5M
$-208.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HHS
HHS
NKTR
NKTR
Q4 25
$737.0K
$-65.0M
Q3 25
$3.2M
$-48.8M
Q2 25
$-4.8M
$-45.7M
Q1 25
$-818.0K
$-49.1M
Q4 24
$4.0M
$-46.2M
Q3 24
$-2.9M
$-43.9M
Q2 24
$1.6M
$-37.7M
Q1 24
$-5.7M
$-47.9M
Free Cash Flow
HHS
HHS
NKTR
NKTR
Q4 25
$-686.0K
$-65.0M
Q3 25
$2.2M
$-48.9M
Q2 25
$-5.1M
$-45.8M
Q1 25
$-923.0K
$-49.1M
Q4 24
$3.4M
$-46.6M
Q3 24
$-4.9M
$-44.6M
Q2 24
$926.0K
$-37.9M
Q1 24
$-6.2M
$-48.0M
FCF Margin
HHS
HHS
NKTR
NKTR
Q4 25
-1.7%
-298.0%
Q3 25
5.5%
-414.5%
Q2 25
-13.1%
-409.6%
Q1 25
-2.2%
-469.0%
Q4 24
7.3%
-159.9%
Q3 24
-10.2%
-184.9%
Q2 24
2.1%
-161.3%
Q1 24
-13.7%
-222.0%
Capex Intensity
HHS
HHS
NKTR
NKTR
Q4 25
3.6%
0.1%
Q3 25
2.5%
1.0%
Q2 25
0.6%
0.3%
Q1 25
0.3%
0.0%
Q4 24
1.3%
1.6%
Q3 24
4.0%
2.8%
Q2 24
1.5%
0.8%
Q1 24
1.2%
0.7%
Cash Conversion
HHS
HHS
NKTR
NKTR
Q4 25
0.33×
Q3 25
Q2 25
Q1 25
Q4 24
-6.36×
Q3 24
-20.76×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HHS
HHS

Fulfillment And Logistics Services$17.3M43%
Customer Care$13.7M34%
Other$8.9M22%

NKTR
NKTR

Segment breakdown not available.

Related Comparisons